## Prescriber Criteria Form

## Phesgo 2025 PA Fax 3987-A v1 010125.docx Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf).

Drug Name:

Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)

Patie	nt Nan	ne:			
Patie	nt ID:				
Patient DOB:		B: Patie	Patient Phone:		
Presc	riber	Name:			
resc	riber	Address:			
City:			: Zip:		
resc	riber	Phone: Preso	criber Fax:		
)iagr	nosis:	ICD (	ICD Code(s):		
nug.	10010.	100	(o).		
Plea	se cir	cle the appropriate answer for each questio	n.		
1	Do	Does the patient have a diagnosis of breast cancer?			No
		[If no, then no further questions.]			
2		Is the disease human epidermal growth factor receptor 2 (HER2)-positive? [If no, then no further questions.]		Yes	No
3	Is the requested drug being used as preoperative/neoadjuvant therapy?  [If yes, then no further questions.]			Yes	No
4	Is the requested drug being used in one of the following clinical settings: A) treatment of recurrent or metastatic disease, B) adjuvant therapy?			Yes	No
Comn	nents:				
-	_	nis form, I attest that the information provided is ion supporting this information is available for re		at the	
Presc	riber (	(or Authorized) Signature:	Date:		